325 related articles for article (PubMed ID: 24023507)
1. HPV infection: immunological aspects and their utility in future therapy.
Deligeoroglou E; Giannouli A; Athanasopoulos N; Karountzos V; Vatopoulou A; Dimopoulos K; Creatsas G
Infect Dis Obstet Gynecol; 2013; 2013():540850. PubMed ID: 24023507
[TBL] [Abstract][Full Text] [Related]
2. Immunity to oncogenic human papillomaviruses.
Konya J; Dillner J
Adv Cancer Res; 2001; 82():205-38. PubMed ID: 11447764
[TBL] [Abstract][Full Text] [Related]
3. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer.
Sasagawa T; Takagi H; Makinoda S
J Infect Chemother; 2012 Dec; 18(6):807-15. PubMed ID: 23117294
[TBL] [Abstract][Full Text] [Related]
4. The current state of therapeutic and T cell-based vaccines against human papillomaviruses.
Yang A; Farmer E; Lin J; Wu TC; Hung CF
Virus Res; 2017 Mar; 231():148-165. PubMed ID: 27932207
[TBL] [Abstract][Full Text] [Related]
5. Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV
Galliverti G; Wullschleger S; Tichet M; Murugan D; Zangger N; Horton W; Korman AJ; Coussens LM; Swartz MA; Hanahan D
Cancer Immunol Res; 2020 Jan; 8(1):131-145. PubMed ID: 31771984
[TBL] [Abstract][Full Text] [Related]
6. An overview of human papillomaviruses and current vaccine strategies.
Gnanamony M; Peedicayil A; Abraham P
Indian J Med Microbiol; 2007 Jan; 25(1):10-7. PubMed ID: 17377346
[TBL] [Abstract][Full Text] [Related]
7. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
8. [Immune response in cervical cancer. Strategies for the development of therapeutic vaccines].
Mora-García ML; Monroy-García A
Rev Med Inst Mex Seguro Soc; 2015; 53 Suppl 2():S206-11. PubMed ID: 26462518
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in vaccination against human papillomavirus-mediated cervical cancer.
McKee SJ; Bergot AS; Leggatt GR
Rev Med Virol; 2015 Mar; 25 Suppl 1():54-71. PubMed ID: 25752816
[TBL] [Abstract][Full Text] [Related]
10. The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma.
Berti FCB; Pereira APL; Cebinelli GCM; Trugilo KP; Brajão de Oliveira K
Cytokine Growth Factor Rev; 2017 Apr; 34():1-13. PubMed ID: 28365229
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus, it's genes...and cancer vaccines.
Steller MA
Cancer Cell; 2003 Jan; 3(1):7-8. PubMed ID: 12559170
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge.
Wang R; Pan W; Jin L; Huang W; Li Y; Wu D; Gao C; Ma D; Liao S
Cancer Lett; 2020 Feb; 471():88-102. PubMed ID: 31812696
[TBL] [Abstract][Full Text] [Related]
13. Design and evaluation of a multi-epitope DNA vaccine against HPV16.
Zhu L; Cui X; Yan Z; Tao Y; Shi L; Zhang X; Yao Y; Shi L
Hum Vaccin Immunother; 2024 Dec; 20(1):2352908. PubMed ID: 38780076
[TBL] [Abstract][Full Text] [Related]
14. Australian HPV vaccination programme yields results.
Howe M
Lancet Oncol; 2014 Dec; 15(13):e591. PubMed ID: 25499291
[No Abstract] [Full Text] [Related]
15. Tumor Immunity and Immunotherapy for HPV-Related Cancers.
Shamseddine AA; Burman B; Lee NY; Zamarin D; Riaz N
Cancer Discov; 2021 Aug; 11(8):1896-1912. PubMed ID: 33990345
[TBL] [Abstract][Full Text] [Related]
16. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy.
Bhat P; Mattarollo SR; Gosmann C; Frazer IH; Leggatt GR
Immunol Rev; 2011 Jan; 239(1):85-98. PubMed ID: 21198666
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
[TBL] [Abstract][Full Text] [Related]
18. HPV induced cervical carcinogenesis: molecular basis and vaccine development.
Kaufmann AM; Backsch C; Schneider A; Dürst M
Zentralbl Gynakol; 2002 Nov; 124(11):511-24. PubMed ID: 12796844
[TBL] [Abstract][Full Text] [Related]
19. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Meric D; Dessy FJ; Datta SK; Descamps D; Dubin G;
Hum Vaccin; 2011 Dec; 7(12):1343-58. PubMed ID: 22048173
[TBL] [Abstract][Full Text] [Related]
20. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]